Post Profile






Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

The first phase III study of PD-L1 inhibitor  atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers report.
read more

share

Related Posts


Medical News Today: Study finds drug improves survival for patients with non-small cell lung cancer

Health : Medical News Today

A new phase 3 trial finds that overall survival is longer for patient with non-small cell lung cancer treated with the drug nivolumab compared with chemotherapy drug docetaxel.

Nintedanib improves progression-free survival but not overall survival in phase III trial of metastatic colorectal cancer

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Nintedanib improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to results of the phase III LUME-colon 1 trial.

First-line pembrolizumab plus chemotherapy significantly improves outcomes in advanced NSCLC

Diseases & Conditions / Cancer : ScienceDaily: Cancer

The addition of PD-1 antibody pembrolizumab to standard first-line chemotherapy for treatment-naïve advanced non-small-cell lung cancer significantly improves response rates and progression-free survival, researchers report.

Ceritinib provides longer progression-free survival than chemotherapy in phase III trial of ALK rearranged lung cancer treatment

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study.

Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) The first phase III study of PD-L1 inhibitor atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, rese...

Comments


Copyright © 2016 Regator, LLC